Format

Send to

Choose Destination
Am J Obstet Gynecol. 2013 May;208(5):354-9. doi: 10.1016/j.ajog.2012.10.885. Epub 2012 Oct 31.

Prenatal treatment of congenital adrenal hyperplasia: risks outweigh benefits.

Author information

1
Department of Pediatrics, University of California-San Francisco, CA, USA. wlmlab@ucsf.edu

Abstract

Prenatal treatment of congenital adrenal hyperplasia by administering dexamethasone to a woman presumed to be carrying an at-risk fetus has been described as safe and effective in several reports. A review of data from animal experimentation and human trials indicates that first-trimester dexamethasone decreases birthweight; affects renal, pancreatic beta cell, and brain development; increases anxiety; and predisposes to adult hypertension and hyperglycemia. In human studies, first-trimester dexamethasone is associated with orofacial clefts, decreased birthweight, poorer verbal working memory, and poorer self-perception of scholastic and social competence. Numerous medical societies have cautioned that prenatal treatment of congenital adrenal hyperplasia with dexamethasone should only be done in prospective clinical research settings with institutional review board approval, and therefore is not appropriate for routine community practice.

PMID:
23123167
DOI:
10.1016/j.ajog.2012.10.885
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center